Perioperative Durvalumab-Enfortumab Vedotin Improves Survival in Bladder Cancer

This phase 3 trial compared perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin against radical cystectomy alone in patients with muscle-invasive bladder cancer ineligible for or declining cisplatin-based chemotherapy. The trial reported significantly improved event-free survival in both durvalumab-containing groups versus surgery alone, and significantly better overall survival with durvalumab-enfortumab vedotin versus control. Grade 3 or higher adverse events of any cause occurred in more than half of patients in both durvalumab groups, compared with 50.2% in the control group.

Most relevant for: Patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.